APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cell-Free Circulating Tumor DNA (ctDNA)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cell-Free Circulating Tumor DNA (ctDNA) Market Outlook and Growth Opportunities 2026

2 May 2026191 pages

Choose your research edition.

Industry ResearchCell-Free Circulating Tumor DNA (ctDNA) Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Cell-Free Circulating Tumor DNA (ctDNA) Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Cell-Free Circulating Tumor DNA (ctDNA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cell-Free Circulating Tumor DNA (ctDNA) Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Cell-Free Circulating Tumor DNA (ctDNA) Market Analysis and Forecast 2026-2032227 pages · $4,950 USD

Market perspective

The global Cell-Free Circulating Tumor DNA (ctDNA) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cell-Free Circulating Tumor DNA (ctDNA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cell-Free Circulating Tumor DNA (ctDNA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cell-Free Circulating Tumor DNA (ctDNA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cell-Free Circulating Tumor DNA (ctDNA) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cell-Free Circulating Tumor DNA (ctDNA) market include Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis and QIAGEN, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Cell-Free Circulating Tumor DNA (ctDNA) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cell-Free Circulating Tumor DNA (ctDNA) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cell-Free Circulating Tumor DNA (ctDNA) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cell-Free Circulating Tumor DNA (ctDNA) market.

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Company

Nexomics

Roche

ORIOMICS

Signatera

Illumina

Sysmex Corporation

Bio-Rad

Biocartis

QIAGEN

GuardantHealth

GSK plc

AstraZeneca

NeoGenomics Laboratories

AmoyDx

Annoroad

Burning Rock Biotech

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Type

Gastric Cancer Methylation Screening

Esophageal Cancer Methylation Screening

Colorectal Cancer Methylation Screening

Lung Cancer Methylation Screening

Liver Cancer Methylation Screening

Other Cancer Screening

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Application

Hospital

Medical Center

Laboratory

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cell-Free Circulating Tumor DNA (ctDNA) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Cell-Free Circulating Tumor DNA (ctDNA) key companies, revenue, market share, and recent developments.

3. To split the Cell-Free Circulating Tumor DNA (ctDNA) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Cell-Free Circulating Tumor DNA (ctDNA) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cell-Free Circulating Tumor DNA (ctDNA) significant trends, drivers, influence factors in global and regions.

6. To analyze Cell-Free Circulating Tumor DNA (ctDNA) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell-Free Circulating Tumor DNA (ctDNA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cell-Free Circulating Tumor DNA (ctDNA) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell-Free Circulating Tumor DNA (ctDNA).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cell-Free Circulating Tumor DNA (ctDNA) industry.

Chapter 3: Detailed analysis of Cell-Free Circulating Tumor DNA (ctDNA) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Cell-Free Circulating Tumor DNA (ctDNA) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Cell-Free Circulating Tumor DNA (ctDNA) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cell-Free Circulating Tumor DNA (ctDNA) Industry Trends Table 2. Cell-Free Circulating Tumor DNA (ctDNA) Industry Drivers Table 3. Cell-Free Circulating Tumor DNA (ctDNA) Industry Opportunities and Challenges Table 4. Cell-Free Circulating Tumor DNA (ctDNA) Industry Restraints Table 5. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Company (2021-2026) Table 7. Global Cell-Free Circulating Tumor DNA (ctDNA) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Cell-Free Circulating Tumor DNA (ctDNA) Key Company Manufacturing Base & Headquarters Table 9. Global Cell-Free Circulating Tumor DNA (ctDNA) Company, Product Type & Application Table 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Cell-Free Circulating Tumor DNA (ctDNA) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Gastric Cancer Methylation Screening Table 15. Significant Companies of Esophageal Cancer Methylation Screening Table 16. Significant Companies of Colorectal Cancer Methylation Screening Table 17. Significant Companies of Lung Cancer Methylation Screening Table 18. Significant Companies of Liver Cancer Methylation Screening Table 19. Significant Companies of Other Cancer Screening Table 20. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type (2021-2026) Table 24. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Hospital Table 26. Significant Companies of Medical Center Table 27. Significant Companies of Laboratory Table 28. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application (2021-2026) Table 32. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application (2027-2032) Table 33. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Region (2021-2026) Table 36. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Region (2027-2032) Table 38. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Market Share by Country (2021-2026) Table 41. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Market Share by Country (2027-2032) Table 43. Nexomics Company Information Table 44. Nexomics Business Overview Table 45. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 47. Nexomics Recent Development Table 48. Roche Company Information Table 49. Roche Business Overview Table 50. Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 52. Roche Recent Development Table 53. ORIOMICS Company Information Table 54. ORIOMICS Business Overview Table 55. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 57. ORIOMICS Recent Development Table 58. Signatera Company Information Table 59. Signatera Business Overview Table 60. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 62. Signatera Recent Development Table 63. Illumina Company Information Table 64. Illumina Business Overview Table 65. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 67. Illumina Recent Development Table 68. Sysmex Corporation Company Information Table 69. Sysmex Corporation Business Overview Table 70. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 72. Sysmex Corporation Recent Development Table 73. Bio-Rad Company Information Table 74. Bio-Rad Business Overview Table 75. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 77. Bio-Rad Recent Development Table 78. Biocartis Company Information Table 79. Biocartis Business Overview Table 80. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 82. Biocartis Recent Development Table 83. QIAGEN Company Information Table 84. QIAGEN Business Overview Table 85. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 87. QIAGEN Recent Development Table 88. GuardantHealth Company Information Table 89. GuardantHealth Business Overview Table 90. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 92. GuardantHealth Recent Development Table 93. GSK plc Company Information Table 94. GSK plc Business Overview Table 95. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 97. GSK plc Recent Development Table 98. AstraZeneca Company Information Table 99. AstraZeneca Business Overview Table 100. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 102. AstraZeneca Recent Development Table 103. NeoGenomics Laboratories Company Information Table 104. NeoGenomics Laboratories Business Overview Table 105. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 107. NeoGenomics Laboratories Recent Development Table 108. AmoyDx Company Information Table 109. AmoyDx Business Overview Table 110. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 112. AmoyDx Recent Development Table 113. Annoroad Company Information Table 114. Annoroad Business Overview Table 115. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 117. Annoroad Recent Development Table 118. Burning Rock Biotech Company Information Table 119. Burning Rock Biotech Business Overview Table 120. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 122. Burning Rock Biotech Recent Development Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Cell-Free Circulating Tumor DNA (ctDNA) Product Image Figure 2. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 4. Global Cell-Free Circulating Tumor DNA (ctDNA) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Gastric Cancer Methylation Screening Image Figure 8. Esophageal Cancer Methylation Screening Image Figure 9. Colorectal Cancer Methylation Screening Image Figure 10. Lung Cancer Methylation Screening Image Figure 11. Liver Cancer Methylation Screening Image Figure 12. Other Cancer Screening Image Figure 13. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Medical Center Image Figure 18. Laboratory Image Figure 19. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application (2021-2032) Figure 22. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Cell-Free Circulating Tumor DNA (ctDNA) Sales Value (2021-2032) & (US$ Million) Figure 25. North America Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Cell-Free Circulating Tumor DNA (ctDNA) Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Cell-Free Circulating Tumor DNA (ctDNA) Sales Value (2021-2032) & (US$ Million) Figure 31. South America Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Gastric Cancer Methylation Screening
  • Esophageal Cancer Methylation Screening
  • Colorectal Cancer Methylation Screening
  • Lung Cancer Methylation Screening
  • Liver Cancer Methylation Screening
  • Other Cancer Screening
Applications
  • Hospital
  • Medical Center
  • Laboratory
Companies covered
  • Nexomics
  • Roche
  • ORIOMICS
  • Signatera
  • Illumina
  • Sysmex Corporation
  • Bio-Rad
  • Biocartis
  • QIAGEN
  • GuardantHealth
  • GSK plc
  • AstraZeneca
  • NeoGenomics Laboratories
  • AmoyDx
  • Annoroad
  • Burning Rock Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Cell-Free Circulating Tumor DNA (ctDNA) Market Dynamics
  1. 2.1 Cell-Free Circulating Tumor DNA (ctDNA) Industry Trends
  2. 2.2 Cell-Free Circulating Tumor DNA (ctDNA) Industry Drivers
  3. 2.3 Cell-Free Circulating Tumor DNA (ctDNA) Industry Opportunities and Challenges
  4. 2.4 Cell-Free Circulating Tumor DNA (ctDNA) Industry Restraints
3 Cell-Free Circulating Tumor DNA (ctDNA) Market by Company
  1. 3.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Company Revenue Ranking in 2025
  2. 3.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Company (2021-2026)
  3. 3.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Company Ranking (2024-2026)
  4. 3.4 Global Cell-Free Circulating Tumor DNA (ctDNA) Company Manufacturing Base and Headquarters
  5. 3.5 Global Cell-Free Circulating Tumor DNA (ctDNA) Company Product Type and Application
  6. 3.6 Global Cell-Free Circulating Tumor DNA (ctDNA) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Cell-Free Circulating Tumor DNA (ctDNA) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Cell-Free Circulating Tumor DNA (ctDNA) Market by Type
  1. 4.1 Cell-Free Circulating Tumor DNA (ctDNA) Type Introduction
  2. 4.1.1 Gastric Cancer Methylation Screening
  3. 4.1.2 Esophageal Cancer Methylation Screening
  4. 4.1.3 Colorectal Cancer Methylation Screening
  5. 4.1.4 Lung Cancer Methylation Screening
  6. 4.1.5 Liver Cancer Methylation Screening
  7. 4.1.6 Other Cancer Screening
  8. 4.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Type
  9. 4.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Type (2021-2032)
  11. 4.2.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type (2021-2032)
5 Cell-Free Circulating Tumor DNA (ctDNA) Market by Application
  1. 5.1 Cell-Free Circulating Tumor DNA (ctDNA) Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Medical Center
  4. 5.1.3 Laboratory
  5. 5.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Application
  6. 5.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Application (2021-2032)
  8. 5.2.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application (2021-2032)
6 Cell-Free Circulating Tumor DNA (ctDNA) Regional Value Analysis
  1. 6.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Sales Value (2021-2032)
  7. 6.3.2 North America Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Sales Value (2021-2032)
  10. 6.4.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Cell-Free Circulating Tumor DNA (ctDNA) Sales Value (2021-2032)
  16. 6.6.2 South America Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Country, 2025 VS 2032
7 Cell-Free Circulating Tumor DNA (ctDNA) Country-level Value Analysis
  1. 7.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Cell-Free Circulating Tumor DNA (ctDNA) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Nexomics
  2. 8.1.1 Nexomics Company Information
  3. 8.1.2 Nexomics Business Overview
  4. 8.1.3 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  6. 8.1.5 Nexomics Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 ORIOMICS
  14. 8.3.1 ORIOMICS Company Information
  15. 8.3.2 ORIOMICS Business Overview
  16. 8.3.3 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  18. 8.3.5 ORIOMICS Recent Developments
  19. 8.4 Signatera
  20. 8.4.1 Signatera Company Information
  21. 8.4.2 Signatera Business Overview
  22. 8.4.3 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  24. 8.4.5 Signatera Recent Developments
  25. 8.5 Illumina
  26. 8.5.1 Illumina Company Information
  27. 8.5.2 Illumina Business Overview
  28. 8.5.3 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  30. 8.5.5 Illumina Recent Developments
  31. 8.6 Sysmex Corporation
  32. 8.6.1 Sysmex Corporation Company Information
  33. 8.6.2 Sysmex Corporation Business Overview
  34. 8.6.3 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  36. 8.6.5 Sysmex Corporation Recent Developments
  37. 8.7 Bio-Rad
  38. 8.7.1 Bio-Rad Company Information
  39. 8.7.2 Bio-Rad Business Overview
  40. 8.7.3 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  42. 8.7.5 Bio-Rad Recent Developments
  43. 8.8 Biocartis
  44. 8.8.1 Biocartis Company Information
  45. 8.8.2 Biocartis Business Overview
  46. 8.8.3 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  48. 8.8.5 Biocartis Recent Developments
  49. 8.9 QIAGEN
  50. 8.9.1 QIAGEN Company Information
  51. 8.9.2 QIAGEN Business Overview
  52. 8.9.3 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  53. 8.9.4 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  54. 8.9.5 QIAGEN Recent Developments
  55. 8.10 GuardantHealth
  56. 8.10.1 GuardantHealth Company Information
  57. 8.10.2 GuardantHealth Business Overview
  58. 8.10.3 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  60. 8.10.5 GuardantHealth Recent Developments
  61. 8.11 GSK plc
  62. 8.11.1 GSK plc Company Information
  63. 8.11.2 GSK plc Business Overview
  64. 8.11.3 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  66. 8.11.5 GSK plc Recent Developments
  67. 8.12 AstraZeneca
  68. 8.12.1 AstraZeneca Company Information
  69. 8.12.2 AstraZeneca Business Overview
  70. 8.12.3 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  72. 8.12.5 AstraZeneca Recent Developments
  73. 8.13 NeoGenomics Laboratories
  74. 8.13.1 NeoGenomics Laboratories Company Information
  75. 8.13.2 NeoGenomics Laboratories Business Overview
  76. 8.13.3 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  77. 8.13.4 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  78. 8.13.5 NeoGenomics Laboratories Recent Developments
  79. 8.14 AmoyDx
  80. 8.14.1 AmoyDx Company Information
  81. 8.14.2 AmoyDx Business Overview
  82. 8.14.3 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  84. 8.14.5 AmoyDx Recent Developments
  85. 8.15 Annoroad
  86. 8.15.1 Annoroad Company Information
  87. 8.15.2 Annoroad Business Overview
  88. 8.15.3 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  90. 8.15.5 Annoroad Recent Developments
  91. 8.16 Burning Rock Biotech
  92. 8.16.1 Burning Rock Biotech Company Information
  93. 8.16.2 Burning Rock Biotech Business Overview
  94. 8.16.3 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  96. 8.16.5 Burning Rock Biotech Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst